Haemonetics (NYSE:HAE) Price Target Cut to $95.00 by Analysts at Barrington Research

Haemonetics (NYSE:HAE) had its price target reduced by Barrington Research from $108.00 to $95.00 in a research note issued to investors on Friday,Benzinga reports. Barrington Research currently has an outperform rating on the medical instruments supplier’s stock.

Other research analysts have also recently issued research reports about the stock. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a report on Friday, November 8th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Price Performance

Shares of HAE opened at $59.34 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09. The company’s fifty day moving average price is $76.94 and its 200-day moving average price is $78.62. Haemonetics has a 1-year low of $59.09 and a 1-year high of $97.97. The firm has a market capitalization of $2.98 billion, a PE ratio of 23.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities research analysts predict that Haemonetics will post 4.59 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Nisa Investment Advisors LLC increased its stake in shares of Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the last quarter. AlphaQuest LLC increased its stake in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 1,826 shares in the last quarter. KBC Group NV raised its holdings in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Haemonetics in the third quarter worth approximately $204,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.